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Preconception care (PCC) is benificial for optimizing women’s health before pregnancy for a 
better pregnancy outcome. In China, a vast majority of pregnancies among married couples 
are planned, providing a unique opportunity for promoting preconception health. However, 
more efficient systems are required to classify prepregnancy risk factors and then manage 
them appropriately. Furthermore, it is important to evaluate the prevalence of preconception 
risk factors and their geographic distribution for health policy planning and appropriate 
allocation of resources. Preconception screening of couples for vertically transmittable 
infections, such as Toxoplasma, Rubella and Cytomegalovirus (TORC), might potentially 
allow implementation of preventive strategies or treatment before conception. However, 
nation-wide prevalence of TORC infection in preconception period and their geographical 
distribution in China is not known.  
Aim and objectives  
The overall aim of this thesis was to evaluate the novel risk classification system in 
preconception care project in China. We have established a sero-epidemiological map of 
TORC infections among married women in China before pregnancy. 
 
The main objectives were: 
1. To evaluate the preconception health status of married couples by a novel risk classification 
system developed by NPHCP. 
2. To investigate the sero-epidemiology of Toxoplasma gondii infection, regional difference 
and related risk factors. 
3. To investigate the sero-epidemiology of Rubella virus infection, geographic characteristic 
and associated socio-demographic factors. 
4. To study sero-epidemiology of Cytomegalovirus infection (CMV), and also its geographic 
and socio-economic factors. 
 
Methods  
This study utilized data extracted from NPHCP during 2010–12. This study was a population-
based, cross-sectional and nation-wide. Its implementation covered 220 rural counties in 
mainland China. All married couples intending to conceive a pregnancy within six months 
were provided free preconception care, and those couples who signed a consent were eligible 
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for inclusion to the study. We excluded those couples who did not sign a consent or failed to 
complete the preconception health examination, and those women did not have their TORC 
infection status.  
Local community staff interviewed married couples of reproductive age regarding their 
conception plans. Those with intention to conceive within six months were enrolled into the 
program. Detailed information on demographic and socioeconomic status was obtained, a 
medical history was taken, and the community health workers performed physical 
examination.  
All the information that was recorded and uploaded in a web-based electronic data collection 
system. Venous blood samples were taken for TORC infection testing. According to the 
amenability to prevention and treatment, preconception risk factors were categorized as 
followed: A-avoidable before conception, B-benefiting from targeted intervention before 
conception, C-controllable but requiring close monitoring during pregnancy, D-diagnosable 
prenatally but not modifiable before conception, and X-pregnancy not advisable.  
Results of TORC serology and collected socio-demographic and clinical data of the 
participating couples were extracted and further analyzed to estimate sero-prevalence in the 
sample population, explore regional differences, and identify associated risk factors.  
 
Results 
Our study enrolled a total of 2142849 couples. Most couples (92.36%) were from rural areas 
in China. 89.2% women and 88.3% men had education below university level. 68.29% 
couples had risk factors before conception, and the risks were mainly of category A, B or C. 
38.13% men were of category A (i.e. avoidable) prepregnancy risk factors, and their female 
countparts were of 11.24%.  
Of 2008561 women who had Toxoplasma gondii serology results, 45405 (2.3%) women were 
IgG positive and 6884 (0.3%) were IgM positive. Advanced maternal age, occupation of a 
farmer, vegetarian diet and exposure to cats were significantly related with Toxoplasma 
gondii IgG and IgM sero-positivity (P=0.000). 
There were a total of 1974188 women with Rubella virus IgG serology results and 
vaccination history. 1161129 (58.4%) were Rubella virus IgG positive and 91604 (4.6%) 
reported history of Rubella virus vaccination. Their self-reported vaccination status did not 
significantly correlate with Rubella virus IgG sero-positivity (P>0.05).  
CMV serology results from a total of 2019555 samples were available, of which 42.1% 
(n=850592) were CMV IgG positive with 0.4% (n=9290) IgM positive. CMV IgG negative 
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women were of younger age, whereas women of advanced age were at higher risk of IgM 
positive (P<0.0001). Provincial CMV IgG sero-positivity was significantly associated with 
resident consumption level (r=0.437; P=0.014) but not with gross domestic product (r=0.167; 
P=0.369).  
Significant regional variations were observed in TORC sero-positivity among married women 
during preconception period.   
 
Conclusions  
This project provided some new insights into preconception care. Preconception health 
screening and use of risk novel risk classification system could effectively identify important 
risk factors and stratify couples into different risk categories. Evaluation of preconception 
health status and stratification of risk showed that avoidable risk factors are most common 
among men, demonstrating the importance of including male partners in preconception care. 
Sero-epidemiological map of TORC infection in China showed that a significant proportion 
of women are susceptible in preconception period. Therefore, targeted screening of these 
infections followed by referral, diagnosis, treatment, counseling, health education and 
vaccination before pregnancy should be considered as appropriate to reduce the risk of 
vertical transmission.   
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Preconception care (PCC) is the provision of health care for women and men planning to have 
a child before conception by World Health Organization (WHO) [1]. Despite the advances in 
prenatal, intrapartum and postpartum care, adverse birth outcomes remain prevalent 
worldwide, even in affluent countries. PCC provides an opportunity to make a difference. 
PCC aims to identify risk factors, promote preventive strategies and provide interventions 
when appropriate. PCC potentially benefits not only the safety of pregnancy and childbirth for 
both mothers and babies, but also long-term consequences on child health and wellbeing [2-4]. 
PCC is shown to prevent unintended pregnancies, congenital birth defects, fetal and neonatal 
infections, and reduce pregnancy complications, as well as maternal and child mortality. 
Therefore, the Centers for Disease Control and Prevention (CDC) recognized that 
preconception health be a critical component of healthcare for women of reproductive age in 
“Providing Quality Family Planning Services” [5-6].  
 
Ideally, preconception health should lead to satisfactory improvement in maternal and infant 
outcomes, however, there are still gaps between available evidence and implementation. On 
one hand, as approximately one third of births are intended [7], in some countries PCC is 
recommended for all women of childbearing age [8]. On the other hand, not all couples 
acknowledge that PCC is important and necessary before conceiving and take pregnancy as a 
biological process without recognizing associated risks. Take folic acid supplement and 
maternal obesity for example. Despite solid evidence that folic acid supplementation is 
significantly benefical for reducing the risk of neural tube defects in the offspring, only 
approximately 30% women take the supplement [9]. Maternal weight has become a public 
concern as overweight and obesity are prevalent worldwide, and maternal obesity has adverse 
effects not only on pregnancy but also on offspring’s health later in life as well [10]. 
Therefore, it is still a challenge to provide effective PCC in the real world, although it is well 
recognized that preconception health matters. PCC is not universally provided even in high-
income countries. Professional guidelines are often lacking and official policies are not 
always in place. Furthermore, the content varies substantially even among European countries 
[11]. 
 
2 HISTORY OF PRECONCEPTION CARE 
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Since the twenty-first century, the focus of maternal health care has shifted from intrapartum, 
antenatal, to preconception care. During the period from the 1960s to the 1980s, maternal 
health care during labor and delivery greatly improved with safer hospital deliveries, 
improved hygiene, availability of antibiotics, safe blood transfusion and surgical techniques, 
and introduction of electronic fetal heart rate monitoring for those high risk pregnancies [12-
15]. This largely contributed to the huge decline of not only maternal mortality caused by 
infection and bleeding, but also of stillbirth and neonatal deaths. The emphasis slowly shifted 
towards antenatal care in the 1980s with the intention of reducing pregnancy complications 
such as anemia, preeclampsia, congenital birth defects and preterm birth. In the past few 
decades, with the realization of the fact that conventional antenatal care is not enough for 
primary prevention, and the growing evidence demonstrating that PCC is effective in 
improving maternal and fetal outcomes, efforts have been made to integrate preconception 
care into traditional antenatal care, interpregnancy care, family planning services and primary 
care. 
The concept of preconception care is not new. However, the ideas and models of 
preconception care have evolved and have been adapted as formalized health policies in 
several countries around the world. Preconception care is focused on the factors prior to 
pregnancy, which need appropriate medical education, prevention and management [16]. 
Each country may have its own model of preconception care with content and purpose 
suitable for the target population. However, the optimal strategy of delivering PCC is yet to 
be determined. The Preconception Service in Hungary [17-18] is mainly targeted at 
prevention of congenital abnormalities and preterm birth from three months with an intended 
pregnancy until the 12th week of pregnancy, including preconception check-up, a 3-month 
preparation for conception and achievement of optimal pregnancy. In this Hungarian 
preconception service, it was found that: (i) the rate of preterm births was reduced from 9.2% 
to 5.0%, mainly due to sexually transmitted infections, (ii) the rate of congenital 
abnormalities was reduced to 2.9%, which mainly linked with periconception multivitamin 
supplementation, (iii) the rate maternal smoking was reduced, (iv) male partners were 
involved, (v) couples at high risk were identified and further transferred to secondary 
specialist care.  The Canadian government also launched a national preconception health care 
project, named the Healthy Life Trajectories Initiative (HeLTI) in 2018 [19]. According to the 
Public Health Outcomes Framework in the United Kingdom [20], PCC is thought to be 
relevant to provide across the whole reproductive life span of couples, in all relevant health 
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and social care pathways. There is a general consensus that PCC is beneficial for achieving a 
better pregnancy outcome and a healthier life of the offspring. In the framework of PCC, both 
women’s as well as men’s health before conception equally contribute to the health of the 
offspring.  
In China, PCC has become a priority concern for maternal and child health since 1990s. A 
series of laws have been passed and policies have been published, including the "Maternal 
and Child Health Care Act” in 1994 which legalized the prevention of birth defects, such as 
by folic acid supplement and avoiding exposure to teratogens for primary prevention, 
screening, diagnosis and termination of pregnancy when a serious defect is found for 
secondary prevention, and diagnosis and treatment after birth. In the decade of 1998-2008, 
relevant guidelines and technology standards were issued as listed in Figure 1, improving the 
preventative strategies of birth defects. In the process of health reform, more financial support 
has been provided, including a national free folic acid supplement program, neonatal health 
insurance for babies born with congenital heart disease, hemophilia, and cleft lip/palate, and 
thalassemia screening in Guangxi, Hainan and Yunnan province. A systemic network of birth 
defects monitoring has been built up since 1986, covering nearly 800 hospitals at county and 
city level. According to the requirement of “National Medium-and Long-Term Science and 
Technology Development Plan (2006-2020)” on the prevention of birth defects, abundant 




Figure 1 Timeline for governmental policy and measures for improving maternal and child 
health during 1994-2012 in China. 
 
3 THEORIES OF PRECONCEPTION CARE 
The importance of improving maternal and child health is well recognized and some 
components of PCC are shown to have a positive effect, whether the concept of universal 
PCC is necessary, feasible and effective still remains controversial. Hence, a careful analysis 
theory is needed.  
3.1 Precautionary principle for the necessity of preconception care 
Initially, the concept of PCC originated from the precautionary principle. According to this 
theory, uncertain issues should be acted on, implying that we’re responsible to protect the 
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public from harmful exposure. Further scientific evidence is required to relax the protection. 
The essence of this principle is captured in PCC (Figure 2).  
The use of bisphenol A (BPA) is a good example of the application of the precautionary 
principle. Exposure to BPA is common in daily life, as it is used in many things including 
computers, cooking appliances, bottles, food containers, etc. Considering the potential risk to 
human health and environment, in the European Union, use of BPA is within a 
comprehensive legislative framework. The classification, labeling and packaging of BPA are 
required to comply with the CLP (classification, labelling and packaging) Regulation (EC No 
1272/2008) to ensure that workers and consumers are clearly communicated for potential 
hazards. In Canada, consumer exposure to BPA is reconfirmed as very low, but the use of 
BPA in baby feeding bottles has continued to be restricted in Canada since 2010.  
Similarly, according to epigenetic principles, intrauterine stress may impact offspring’s’ 
health without alteration of the gene sequence, which could possibly be related with DNA 
methylation and histone modifications [21-22]. Evidence from animal models showed 
epigenetic modifications in offspring’s health, and epidemiological evidence suggests that this 
could also be the case in humans [23-24], such as impaired deoxyribonucleic acid (DNA) 
methylation of insulin-like growth factor-2 (IGF-2) among offspring of women prenatally 
exposed to starvation during the Dutch famine [25-27]. Therefore, it is logical to think that 
adequate and balanced nutrition before and during pregnancy is likely to be beneficial for the 
health of woman as well as long-term wellbeing of the child. 
In the “Barker hypothesis” [28-30], the concept of developmental origins of health and 
disease (DOHAD) proposes that one’s intrauterine environment and early childhood health 
affects one’s health later in life. Therefore, eliminating or reducing maternal exposure to 
harmful substances (e.g. teratogens, smoking, drugs etc.), unfavorable environments (e.g. 
hypoxia), malnutrition (such as overweight, underweight), endocrine disbalance (e.g. 
hyperglycemia, hypothyroidism, etc.), could potentially improve perinatal outcomes and help 
achieve a healthier status in later life.  
Thus, health policy makers and healthcare professionals are getting interested in making PCC 




Figure 2. Precautionary principle for the necessity of preconception care. 
3.2 Theory of change for the feasibility of preconception care  
The implementation of PCC is more than a combination of healthcare and social reform. In a 
public health perspective, Theory of Change (ToC) is applied to the practice of PCC. In ToC, 
long-term goals are defined first, and then the necessary preconditions are identified 
backwards. The practice of PCC in China is based on the ToC, considering the factors of 
society, economics, health service, knowledge of couples and social behaviors. Its framework 
consists of four aspects, i.e. background, activities, changes and results, considering political 




Figure 3. Theory of Change as applied to preconception care in China. 
3.3 Translational medicine for the effectiveness of preconception care 
The translation from research populations to general population is the requisite for an 
effective PCC. In the practice and policy decision making of PCC, translational medicine 
works based on the following four aspects: (1) risk factors before pregnancy are associated 
with adverse pregnancy outcomes in epidemiological study and basic experimental 
laboratory-based research; (2) intervention before conception is feasible; (3) the 
preconception risk is an actual problem in the real world; (4) intervention before conception is 
effective in real world population (Figure 4).  
 
Figure 4. Translational medicine for the effectiveness of preconception care. 
There are several examples of translational research influencing health policies regarding 
preconception care, such as national recommendations on folate intake for women of 
reproductive age and folic acid supplement for reducing the risk of congenital birth defects 
[31]. 
 
4 RISK FACTORS DURING PRECONCEPTION PERIOD 
There is abundant evidence showing that PCC is beneficial to women and children’s health as 
it has the potential to eliminate or modify pre-pregnancy risk factors. Interventions including 
avoiding exposure to alcohol, smoking, and substance abuse, are expected to have a positive 
effect on promoting healthier lifestyle [32], besides that folic acid supplementation [33], 
immunizations, and treatment of sexually transmitted infections are well recognized to 
improve pregnancy outcomes. Since PCC is defined as biomedical, behavioural and social 
health interventions by WHO [1], the above three aspects of risk factors during preconception 
period are addressed here. Therefore, the prevalence, amenability to modification, and 
feasibility of intervention of prepregancy risk factors need to be evaluated in well-defined 
populations taking into account their ethnic, social, cultural and economical backgrounds. 
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4.1 Biomedical risk factors 
Immunization is practical and feasible before pregnancy and it is known to improve 
pregnancy outcomes from vaccine preventable diseases. Rubella infection in pregnancy has 
greatly declined since the introduction of MMR immunization, and therefore, the risk of fetal 
loss and congenital rubella syndrome (CRS) has significantly decreased [34].  
Taking folic acid supplement is widely accepted as it substantially reduces the risk of neural 
tube defects (NTDs) [35] and cardiovascular malformations.  
Effective treatment of chronic diseases including diabetes and hypertension, during the 
preconception period seems to be benefical for reducing adverse maternal and neonatal 
outcomes [36-38]. 
4.2 Behavioral risk factors  
Smoking during pregnancy is closely related with premature births, miscarriages, stillbirth 
and low birthweight [39]. Passive (second-hand) smoking is significantly prevalent among 
Chinese women as maternal smoking rate before conception was reported to be only 0.45% 
with a paternal smoking rate of 29.07% [40]. Concern regarding the role of paternal smoking 
on birth defects is growing. Animal studies have found potential toxic effect of paternal 
exposure to smoking on sperm development [41], and epidemiological evidence indicates an 
association between fathers’ smoking and conotruncal heart defects, limb reduction defects 
and amniotic band syndrome [42]. 
Alcohol is a ‘teratogen’ affecting fetal development and causing birth defects [43]. Alcohol 
consumption is associated with a higher risk of not only fetal growth restriction, but also 
preterm birth and perinatal mortality as well. Prevalence of maternal alcohol consumption in 
preconception period was approximately 3.40% and, therefore, it is important to stop or 
reduce alcohol consumption before pregnancy in order to eliminate potential risks [40].  
A comprehensive family planning service as a component of PCC is instrumental for avoiding 
unintended pregnancies, which could avert up to 44% maternal mortality [44]. It can also 
reduce the risk of sexually transmitted diseases, Hepatitis B virus and HIV infections. 
4.3 Social risk factors 
Maternal age is an important social factor related with adverse pregnancy outcomes. Teenage 
pregnancy is at increased risk of preeclampsia, stillbirth, preterm birth, perinatal infection and 
neonatal intensive care unit (NICU); a similar association has been observed among women 
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of advanced age, with the threshold age at 35 or 40 years old [41-49]. In China, the two-child 
policy has been implemented since 2016, replacing the previous one-child policy. Related 
social and psychological risks have grown along with the aging population and cultural 
change [50].  
 
5 NATIONAL FREE PRECONCEPTION HEALTH EXAMINATION PORJECT IN 
CHINA  
5.1 Background of the National Preconception Health Examination Project 
A well-organized delivery system of PCC, awareness among future parents about the benefits 
and awareness among healthcare professionals about the effectiveness are requiste to achieve 
a good PCC service [51-52]. 
In China, PCC has become more important than ever. Population health has greatly 
imporoved with a rapid economic development in recent decades. Healthcare facility-based 
delivery strategy including birth care in the community by a skilled provider significantly 
reduced neonatal mortality for the Millennium Development Goal 4 [53]. According to 
national health surveillance, maternal mortality has decreased by 75.6%, from 88.8/100,000 
in 1990 to 21.7/100,000 in 2014, and the neonatal mortality was 0.89%. However, there are 
some concerns. Firstly, according to the Birth Defects Report in China in 2012, the 
prevalence of birth defects was increased to 5.6%, which has been attributed to decreased rate 
of voluntary premarital medical examination [54]. Secondly, China has shifted to a two-child 
policy for countermeasuring the aging population and shrinking labor supply [55], which has 
led to an increasing portion of women of advanced age and with previous cesarean section 
being pregnant. Thirdly, geographic diversity is prominent; the maternal mortality rate in 
western areas is 2.6 times higher and child mortality before the age of 5 is 3.1 times higher 
compared to that in eastern areas. Additionally, there are gaps in accessibility and 
affordability of healthcare between urban and rural areas. 
Although the benefits of PCC have been well recognized, the integration of PCC into 
women’s healthcare still remains challenging. PCC in rural China used to be insufficient and 
inadequate as there are limited medical resources and there is a lack of adequate healthcare 
facilities and coverage by national health insurance. Women in rural China are more likely to 
be under-nourished, anemic, and have infectious diseases. They are likely to be less educated, 
have low socio-economic level and work as farmers or as urbanized immigrant workers. Thus, 
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the Chinese government introduced a series of health policies to establish a new health 
insurance system, including the provision of maternity leave and economic support after 
delivery, and the free National Preconception Health Care Project (NPHCP).  
5.2 Framework of the National Preconception Health Examination Project 
This project is a nationwide, community-based, welfare program sponsored by the 
government of People`s Republic of China. The project is based on the concept that 
preconception care is a beneficial option for the prevention of birth defects, stopping smoking, 
controlling alcohol consumption, promoting balanced nutrition, screening population for 
genetic risk factors, chronic and infectious diseases, providing education, counselling and 
medical advice, and facilitate referral to specialist healthcare when needed.  
5.3 Implementation of the National Preconception Health Examination Project 
Preconception health evaluation is free to all married couples living in the 220 pilot counties. 
The target population consists of both wife and husband with an intention to conceive within 
six months [40, 55]. The healthcare is provided during the preconception period, and extended 
from early pregnancy to postpartum period, with the goal of achieving a healthier 
prepregnancy status and improving pregnancy outcomes [56]. Practical implementation of the 
project is carried out in village/town-county bases or in direct county bases as illustrated in 
the flow charts (Figure 5, 6). Community staff and local hospital staff who are trained, 
qualified and are familiar with the published project contents and standards, are responsible 









Figure 6. Flow chart demonstrating implementation of NPHCP in direct county base. 
 
6 CURRENT PRECONCEPTION RISK CLASSIFICATION SYSTEMS AND 
NOVEL RISK CLASSIFICAITON IN CHINA 
6.1 Current classification systems 
The majority of risk factors before conception are avoidable, preventable or treatable [57]. 
These risks are generally classified based on the type of disease or exposure (such as genetic, 
reproductive, chronic disease, infectious, nutritional, behavioral, occupational, environmental 
and social risks). They are sometimes classified based on adverse outcomes in the mother or 
the fetus (maternal and fetal), or by severity of risk. Identifying and evaluating preconception 
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risk is cumbersome and time-consuming but a comprehensive risk assessment is required. In 
the Netherlands, ZwangerWijzer is the most widely used self-administered online 
questionnaire, covering environmental, occupational, lifestyle and genetic risk factors. A 
personalized PCC is subsequently provided according to the identified risk factors [58-59]. 
Abundant prepregnancy risk factors have been reported, and thus, there is a necessity for PCC 
providers to manage the risk factors based on their impact, priority and feasibility of 
intervention to improve subsequent pregnancy outcomes.  
6.2 Novel preconception risk classification model in China 
In China, in order to better classify and manage the risk factors before conception, a novel 
risk classification system has been introduced in NPHCP that groups prepregnancy risk 
factors according to their amenability to prevention and treatment [56]. Preconception Health 
Examination and Risk Evaluation Guides were publicly published, which listed classification 
and treatment advices in details [40]. Preconception risk factors were categorized into the 
following five groups: A-avoidable before conception, B-benefiting from targeted 
intervention before conception, C-controllable but requiring close monitoring during 
pregnancy, D-diagnosable prenatally but not modifiable before conception, and X-pregnancy 
not advisable [40, 56]. Whether this novel classification system is feasible and efficient in 
classifying prepregnancy risk factors needs to be further evaluated. Furthermore, neither 
distribution of prepregnancy risk factors among Chinese couples, nor their amenability to 
intervention has been assessed. More research is needed regarding the impact of maternal 
healthcare strategy and novel risk classification model on stratifying risk factors and the 
preconception health status.  
 
7 INFECTIONS AND PRECONCEPTION HEALTH   
Infections are a major cause of adverse pregnancy outcomes. Approximately 30-50% preterm 
births (PTB) are related with maternal infections, and urogenital infections are well 
recognized as an important contributing factor to PTB and neonatal sepsis. Screening for 
group B streptococcus (GBS) is recommended in several countries. Systemic infections, such 
as TORCH (Toxoplasma, Rubella virus, Cytomegalovirus and Herpes Simplex), syphilis, 
Hepatitis B virus and HIV are a significant cause of maternal, fetal and neonatal adverse 
outcomes. Thus, screening to identify susceptible or infected women and offering 
immunization or other preventive measures as well as treating infected women before 




Antenatal screening strategies for infections vary worldwide: in the USA, UK and most 
Scandinavian countries, pregnant women are screened for Rubella and syphilis at their first 
prenatal visit, while in some other countries, such as Germany and France, they may also be 
screened for Toxoplasmosis and CMV. Asymptomatic infants are generally not screened for 
congenital infections in most counties.  
 
Ethnic and socio-economic disparities regarding infectious morbidity are well described. In 
the USA, urogenital infection is more common among Black women compared to their White 
ccouterparts, which is closely associated with not only preterm premature rupture of 
membranes but also preterm birth. Whether similar disparity exists among Chinese women of 
different genetic, cultural and socio-economic backgrounds has not been investigated. 
Furthermore, the prevalence of infections in preconception period in different geographic 
regions of China is not known. However, this knowledge would be important to develop 
policy on preconception healthcare.  
 
8  TORCH INFECTIONS 
TORCH infections have a potential risk of vertical transmission causing congenital infection. 
They are associated with serious risk of maternal, fetal and neonatal morbidity and mortality.  
 
8.1 Toxoplasma gondii 
Toxoplasma gondii (T. gondii) is an intracellular protozoan parasite. It infects both animals 
and humans, and is widely prevalent worldwide. Cats shed oocysts in their feces after 
ingesting any of the any stages of T. gondii, including tachyzoites, bradyzoites and 
sporozoites, which are contained in infected raw meat. Humans can get infected when they 
come in contact with oocysts shed by cats or by ingesting infected raw meat. In humans, 
ingested oocysts or tissue cysts transform into tachyziotes representing acute infectious stage 
of the disease and localize in neural and muscle tissues. Later, they develop into bradyzoites 
and remain dormant except in immunocompromised individuals.  
Pregnant women are at risk of acquiring infection if they eat raw meat, have contact with cat 
litter or contaminated soil. Infection is usually asymptomatic, but transplacental transmission 
can occur causing congenital infection in the fetus. The risk depends on the timing of 
infection (seoconversion), varying from approximately 10-15% transmission rate in the first 
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trimester to 60-70% in the third trimester. However, congenital infections tend to be more 
severe earlier in gestation, potentially leading to miscarriages and stillbirths. Fetal infection is 
associated with increased risk of intracerebral calcifications, hydrocephalus, 
meningoencephalitis, and retinochoroiditis [60-62].  
T. gondii is prevalent worldwide, and it infects approximately 33% of the world’s population 
[63]. Its sero-positivity among pregnant women varies, ranging from 60% in Brazil to less 
than 10% in the United Kingdom [64]; geographic difference is notable for the incidence of 
congenital infection: varying from 0.1% live births in France, to 0.01% in the USA [65]. 
Prevalence of T. gondii sero-positivity in some provinces in China was relatively low [66], 
but nation-wide sero-epidemiology is unclear.  
Some risk factors for T. gondii infection are avoidable, especially eating raw meat and contact 
with cats [67-68]. In addition, educational level and awareness of risk as well as hygiene play 
an important role in disease transmission. Considering that it is common to have domestic 
cats in rural areas and the possibility of lower hygienic standards compared to urban areas, the 
risk of Toxoplasma gondii infection was expected to be higher in rural areas. The risk factors 
for maternal-fetal transmission include advanced gestational age at maternal infection, high 
parasite load, parasite source from sporozoites in oocysts, high-virulence T. gondii strain, and 
maternal immunocompromise. The distribution of risk factors may vary geographically, but 
the information regarding regional differences in prevalence of Toxoplasmosis in China is 
scarcely available. 
Maternal infection is generally asymptomatic, nonspecific and mild. The mother could have 
fever, fatigue, chills, sweating, headaches, myalgias, pharyngitis, lymphadenopathy, 
hepatosplenomegaly, and nonpruritic maculopapular rash. More importantly, it is critical but 
difficult to determine the timing of infection among asymptomatic pregnant women. Primary 
prevention strategy seems a safer option to reduce the risk of congenital infection, because 
there is no effective vaccine against Toxoplasma [69]. Also, there still lacks sufficient 
evidence for an effective prenatal treatment to reduce the risk of mother to child transmission 
[70]. It is recommended to delay pregnancy for six months after an acute infection since the 
parasitemia is short lived and the infected women would have developed adequate immunity 
by then. Studies in Europe and North America have shown that maternal treatment within 
three weeks of seroconversion is beneficial for reducing vertical transmission and serious 
neurological sequelae or death in congenitally infected offspring [71]. However, majorities of 
women of childbearing age are susceptible to primary infection and are at risk of congenital 
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toxoplasmosis and its sequelae. Therefore, prepregnancy screening for T. gondii infection 
should be a good option for better primary prevention of congenital infection.        
8.2 Rubella virus 
Congenital rubella syndrome (CRS) is regarded as a public health concern. Rubella is a viral 
infection, which was known as German measles. Rubella virus is infectious only to humans. 
Rubella outbreaks have continued in some countries, and Although Rubella virus infection is 
generally self-limiting, the risk of transplacental transmission is high if the infection occurs 
during pregnancy. Rubella infection during pregnancy may cause miscarriage, preterm birth, 
stillbirth and intrauterine growth restriction [72]. CRS is associated with deafness, ophthalmic 
defects (e.g. cataracts, chorioretinitis, microphthalmia), cardiac defects, neurological 
abnormalities (e.g. microcephaly, meningo-encephalitis, mental retardation) and other defects, 
such as hepato-splenomegaly, bone defects, thrombocytopenia, purpuric skin lesions). 
The risk of congenital infection varies with gestational age. Fetal infection rates are 
approximately 81% in the first trimester, dropping down to 25% in the second trimester, and 
rising to nearly 100% after 36 weeks [73]. However, severe sequalae is mostly limited to 
infection occurring before 16 weeks of gestation. Currently, effective treatment for in utero 
Rubella virus infection is still not available. 
Maternal immunity is effective for protecting against intrauterine Rubella infection. It is 
acquired not only naturally but also by vaccine. The risk of CRS can be eliminated, by 
screening to identify susceptible women and offering vaccination before pregnancy. If 
antibodies to Rubella are negative, it provides the woman an opportunity to get vaccinated 
before conception, in order to avoid the risk of CRS. Immunization before conception is 
important in susceptible women to ensure that Rubella virus IgG are positive before or in 
early pregnancy because none of the CRS resulting from maternal reinfection occurred in 
women infected after 12 weeks of pregnancy [74]. It is recommended to avoid conception at 
least by one month following the administration of Rubella vaccine due to theoretical risk to 
the fetus with live attenuated vaccine.  
In many countries screening for Rubella antibodies is performed routinely during the first 
trimester of pregnancy. Although it allows counseling regarding the risk, providing some 
advice on how to avoid infection in the current pregnancy and offer immunization postnatally, 
the risk of infection during pregnancy cannot be completely avoided. 
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Prevalence of Rubella susceptibility among women of reproductive age varies worldwide. In 
China, the nation-wide incidence of Rubella was 9.11/100,000 in 2008 according to the 
National Notifiable Diseases Reporting System (NNDRS) [75] while the annual incidence 
rate of Rubella was reported to be only 0.75 per 100,000 in Zhejiang province in 2013-15 [73]. 
The rate of CRS in live births was 0.9% in Jinan and Yantai [76]. In the Russian Federation, 
approximately 16.5% of pregnant women were susceptible to Rubella infection, and 
prevalence of CRS was 0.35% [77]. In Turkey, it was estimated that 15% of women aged 20-
29 have negative titers [78], and 23% of reproductive women were reported to lack antibodies 
to Rubella in Nigeria [79].  
Vaccination strategy is effective and recommended for protecting from Rubella virus 
infection. Routine vaccination with measles, mumps, and Rubella combination vaccine 
(MMR) in childhood, and measles, mumps, Rubella, and varicella combination vaccine 
(MMRV) are beneficial for reducing CRS. For example, the incidence of Rubella in the 
United States declined to 0.1 per 100,000 in 1999 [80-82]. However, it is not always optimal 
for vaccination coverage. In China, MR and MMR vaccinations during infancy and childhood 
were expanded in 2005 [83]. However, there lacks nation-wide prevalence of Rubella virus 
IgG sero-positivity among Chinese women of childbearing age before conception. 
8.3 Cytomegalovirus 
CMV is a ubiquitous DNA virus. It can be found in the urine or cervix of 2-28% pregnant 
women. Although CMV infection is common, in immunocompetent adult individuals a vast 
majority of infections (>90%) are subclinical. However, infection during pregnancy could 
possibly lead to serious fetal infection. Viral transmission occurs tranplacentally or during 
birth from exposure to maternal cervicovaginal secretions and blood. Maternal immunity is 
beneficial for the fetal protection as maternal IgG positivity significantly reduces the risk of 
intrauterine infection [84]. However, nearly 970,000 women of childbearing age were 
reported to have a primary CMV infection each year in the United States [85]. The prevalence 
of congenital CMV is 0.64% at birth, and it’s one of the most common virus infections during 
pregnancy [83].   
In utero CMV infection may occur after maternal primary or recurrent infection during 
pregnancy, but symptomatic congenital CMV are mainly observed in primary maternal 
infection. Hearing loss and mental impairment, including seizures and cerebral palsy, are the 
most common manifestations of congenital CMV infection. Prenatal antiviral treatment has 
been used, but it remains controversial due to associated drug toxicity. Sufficiently safe and 
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effective treatment is still lacking. Therefore, it is suggested that women consider delaying 
conception at least 6 months after primary infection [86-87]. Compared with seroconversion 
during pregnancy, preconception seroimmunity provides a more substantial protection against 
maternal-fetal infection. Thus, determining CMV serology status before conception and 
providing proper counseling, information and support might help to reduce the risk vertical 
transmission. 
CMV IgM and IgG are used as serological markers of infection and immunity. Women who 
are IgG positive are considered at low risk of infection while those who are IgM positive may 
have current infection. Since IgM antibodies could be detected 6-8 months after the infection, 
the timing of maternal infection is difficult to determine. Avidity assays may be of some help 
as low avidity suggests recent infection.  Prenatal diagnosis by amniocentesis and polymerase 
chain reaction (PCR) for CMV DNA may be offered to women diagnosed as primary 
infection or if fetal infection is suspected on ultrasound examination. 
IgG sero-positivity was reported to be 98.7% among pregnant women living in Jiangsu 
province in China [88]. Substantial regional variation in CMV sero-positivity has been 
observed in the USA with seropositivity differing by race and/or ethnicity. Compared with 
their non-Hispanic white Americans, non-Hispanic Black and Mexican Americans were at 
higher risk of infection [77].  
In the United States and Europe, 40% of women of childbearing age are considered to be 
susceptible to CMV. However, studies on prevalence of CMV sero-positivity among women 
planning a pregnancy are scarce and whether identification of susceptible women before 
pregnancy and subsequent preventive strategies could reduce vertical transmission has not 
been properly explored. A recent study of women with fertility treatment showed that 
preconception testing and counseling is helpful for minimizing exposure to CMV by 
improving personal hygiene might have a positive effect [89].  CMV vaccine could be a 
future option for eliminating maternal-fetal transmission. Despite their potential in preventing 
congenital CMV, vaccines is currently not available, but they are under clinical development 
[90]. Therefore, preconception screening and treatment of CMV may be useful in reliefing the 
burden of congenital infection, at least in areas with high susceptibility rates. 
8.4 Herpes simplex virus 
Herpes simplex virus (HSV) is subgrouped into HSV type 1 (HSV-1) and HSV type 2 (HSV-
2) [91-93]. HSV-2 primarily causes the genital herpes and HSV-1 for herpes labialis, 
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gingivitis, stomatitis and kerato-conjunctivitis. However, genital infections due to HSV-1 are 
becoming common in recent years, perhaps due to changing sexual practices. HSV is 
transmitted through direct contact and genital herpes is a sexually transmitted infection. 
During primary infection, vesicles appear on the vulva which then break leaving ulcers that 
heal in 2-3 weeks. Reactivation of viral replication can lead to recurrent ulcerations or 
asymptomatic shedding of virus. 
Genital HSV infection has three clinical subtypes: i) primary infection with HSV-1 and HSV-
2 antibodies negative, ii) nonprimary first-episode (first genital infection with HSV-1 with 
pre-existing HSV-2 antibodies or genital infection with HSV-2 and pre-existing HSV-1 
antibodies), and iii) recurrent infection, i.e. HSV type in the genital lesion and antibody type 
in the serum are same [87]. The seroprevalence of HSV differs depending on the subtype of 
virus: sero-positivity rate of HSV-2 decreased by 50% from 30% to 16% during 1990-2010, 
with a stable rate of HSV-1 at 65-69% [94-95].  
Maternal-fetal transmission of HSV usually results from infected genital secretions during 
labor and delivery. Ascending infection occurs rarely. However, primary HSV infection 
acquired in the first trimester is correlated with miscarriage, preterm birth and fetal 
intrauterine growth restriction, choriortinitis and microcephaly [94-98]. Primary infection in 
late pregnancy may cause localized lesions in the skin, eye, mouth and central nervous system 
in the neonate. Regardless of the timing of infection and virus subtype, acyclovir is 
recommended as suppressive therapy from 36 weeks of pregnancy until the onset of labor for 
reducing the risk of disease recurrence and vertical transmission [99-100], and some 
recommend elective cesarean section in cases with active vulvo-vaginal lesions. Whether to 
perform a universal antenatal serologic screening remains controversial.  Serologic screening 
might be helpful to inform infected women regarding standard suppressive antiviral therapy, 
and give advice on avoiding new infection during pregnancy to women with negative HSV 
antibodies. However, universal screening strategy still needs further evaluation. 
In NPHCP, universal TORC (Rubella IgG antibody, CMV IgM and IgG antibody, 
Toxoplasma IgM and IgG antibody) serological screening was provided to all participating 
couples. However, data on serological profile of HSV were not collected in the NPHCP 
project. Thus, we were not able to evaluate the seroprevalence of HSV. We focused on 
establishing the sero-epidemiological map of TORC infections among married women in 




9 AIMS OF THE STUDY 
Delivering PCC at a population level is complex and many questions still remain to be 
answered. As pregnancies among married couples in China are mostly planned, this presents 
the opportunity to deliver PCC services in a structured manner. However, for appropriate 
allocation of resources and organization healthcare systems to deliver effective PCC services, 
it is of importance to know the distribution of prepregnancy risk factors and their amenability 
to intervention. Infections, such as TORC, that can be vertically transmitted from mother to 
fetus are a major risk factor during pregnancy, but their nationwide prevalence, regional 
differences in sero-epidemiology and feasibility of intervention in preconception period to 
improve pregnancy outcomes has not been studied well in China.  
The overall aim of this thesis was to evaluate the impact of preconception health screening 
strategy and a novel risk classification system of China´s “National Preconception Health 
Care Project (NPHCP)”, and to establish a sero-epidemiological map of TORC infections 
among Chinese married women before conception. 
The main objectives were: 
1. To evaluate the preconception health status of married couples by a novel risk classification 
system developed by NPHCP. 
2. To investigate the sero-epidemiology of Toxoplasma gondii infection, regional difference 
and related risk factors. 
3. To investigate the sero-prevalence of Rubella virus infection, geographic characteristic and 
associated socio-demographic factors. 
4. To study sero-epidemiology of Cytomegalovirus infection (CMV) in preconception period 




10.1 Study design and settings 
This study utilized data collected by NFHCP between 2010–12. It covered 220 predominantly 
rural counties located in 31 provinces and province level municipalities of China. In 2010, 
NFHCP was launched by the Chinese National Health and Family Planning Commission and 
Ministry of Finance. Local community staff interviewed married couples of reproductive age 
regarding their conception plans. Those with intention to conceive within six months were 
enrolled into the program. They were provided with a free PCC package that included 20 
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preconception health service items including preconception health check-ups and referral to 
specialized hospitals [40, 56-57]. Couples who did not complete preconception examination 
and women with missing TORC serology test results were excluded from analysis.  
10.2 Contents of the National Preconception Health Examination Project 
Basic items of NPHCP are presented in Table 1. Preconception health examination included: 
(1) current medical histor; (2) physical examination; (3) clinical laboratory test; (4) past 
medical history; (5) previous obstetric history.  
Table 1. Basic items included in National Preconception Health Examination Project. 
 Items Female Male 
1 Health education √ √ 
2 Medical history (pregnancy history, disease history, family history, drug use, lifestyle, nutrition, environmental factors) √ √ 
3 Physical exam 
Regular exam (height, weight, blood 
pressure, heart rate, thyroid palpation, 
cardiopulmonary auscultation, 
abdominal palpation, limb and spine 
exam) 
√ √ 





Leucorrhea routine √  
Gonococcus test √  
Chlamydia test √  
5 Blood routine √  
6 Urine routine √ √ 
7 Blood type √ √ 
8 Fasting glucose test √  
9 Glutamic-pyruvic transaminase √ √ 
10 Hepatitis B serology √ √ 
11 Creatinine √ √ 





Treponema pallidum screening √ √ 
14 Rubella (IgG antibody) √  
15 Cytomegalovirus (IgM and IgG antibody) √  
16 Toxoplasma (IgM and IgG antibody) √  
17 Imaging exam Gynecological ultrasound exam √  
18 Risk evaluation and consultation √ √ 
19 Follow-up in early pregnancy   
20 Follow-up of pregnancy outcomes √  
 
General information including age, residence address, education, occupation, ethnicity, 
medical history and reproductive history were collected using a standardized questionnaire for 
wife and husband respectively. A real-time central database was built up for a continuous 
follow-up and data collection from preconception, early pregnancy to postpartum period 
(Figure 7).  
 
Figure 7. Diagram of the National Preconception Health Examination Project. 
The detailed data collection forms included family health file, informed consent, female 
examination form, male examination form, examination result and evaluation notification, 
follow-up records in early pregnancy, follow-up records of pregnancy outcome and records of 
birth defects. These data were collected at the community base as demonstrated in Table 2. 
The details of the data collection forms translated from Chinese are included as an appendix 1.  
Table 2. Data collection of the National Preconception Health Examination Project. 
Data forms Data collecting authority 
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Family health file Village/town/county-based health care authority 
Informed consent Village/town/county-based health care authority 
Female examination form County-based health care authority 
Male examination form County-based health care authority 
Examination result and evaluation 
notification County-based health care authority 
Follow-up records in early pregnancy Village/town/county-based health care authority 
Follow-up records of pregnancy outcome Village/town/county-based health care authority 
Records of birth defects Village/town/county-based health care authority 
 
Trained staff regularly uploaded the information into database. For the purpose of studies 
included in this thesis, risk factors, TORC serology and related demographic and clinical 
information were extracted and analyzed. 
10.3 Requirements and training for the National Preconception Health Examination 
Project 
In this project, at least 85% coverage of married couples who intended to conceive was 
required. The absolute numbers of couples that participated in the project were calculated 
based on the statistics reported by the local health administration department and compared 
with the estimates based on local number of births in the previous year [40, 56-57]. The 
requirements and training of health service authorities and staff involved in the project is 




Figure 8. Requirements and training of health service authorities and staff. 
10.4 Quality control of the National Preconception Health Examination Project 
A comprehensive quality control system has been established for this national project. Firstly, 
a national center for examination of family planning services was established, which 
conducted sampling and recheck of lab tests. Secondly, a national database of preconception 
care was built and data entry was checked regularly and monthly quality reports were 
published. In addition, a series of policies were introduced, including quality management of 
health care services, clinical laboratory testing, and databases.  
10.5 TORC testing and follow up 
Five mL of venous blood was sampled and stored at –30°C. All serum specimens were tested 
for TORC antibodies using commercially enzyme immuno-assay kits in local laboratories. 
The cut-off value for sero-positivity was based on the manufacturer’s recommendation for the 
enzyme-linked immunosorbent assay (ELISA) kit. As described previously [56-57], an 
external quality assessment (EQA) was performed by the National Center of Clinical 
Laboratories for Quality Inspection and Detection every six months. 
The interpretation of TORC serology was as follows: positive IgM serology with negative 
IgG titer was considered as acute infection, and those women were referred to specialist 
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accordingly. Negative IgM with positive IgG was considered as low risk of infection due to 
immunity originated from previous infection or vaccination. Negative IgG and IgM was 
considered to be susceptible and those women were advised on how to prevent being infected 
during preconception period and pregnancy, and to have vaccination before conception when 
appropriate. The recalled vaccination history was recorded based on the vaccination records 
when available, such as the vaccination cards, or otherwise self-reports.  
10.6 Statistical analyses 
The database of the National Data Center of Preconception Health Care has been regularly 
updated. According to their residential address, all participanted couples were grouped into 31 
provinces and province level municipalities, and six geographical regions as well. 
Socio-demographic and clinical characteristics were calculated as numbers, proportions, 
means and standard deviations (SD) when appropriate. The chi-squared test was applied for 
comparison of proportions between groups. The multivariate correlation or regression 
analysis were used for analyzing associations between variables. The Spearman correlation 
analysis was used to evaluate the association of CMV serology (IgG and IgM) status with 
grosss domestic product (GDP) and resident consumption level, as these variables had skewed 
distribution. A two-sided P-value<0.05 was regarded as statistically significant. SPSS version 
22.0 (IBM Corp, Armonk, NY) and R software version 3.2.2 (https://www.r-project.org) were 
applied for statistical analyses. Geographic mapping was drawn using ArcGIS version 10.2. 
10.7 Ethical considerations 
PCC involves risk assessment, health promotion, counseling, and interventions to modify or 
eliminate risks. During PCC, couples’ decision-making regarding pregnancy is influenced by 
provided information about their reproductive choices and options that may help to improve 
pregnancy outcomes. Through PCC the couples could be helped to optimally prepare their 
minds and bodies for a pregnancy. However, the implementation of universal PCC at a 
national level is still controversial. On the other hand, some may consider it as a moral 
responsibility. In China, free PCC services were introduced as a national public health 
program. This projected was approved by the Institutional Review Board of the Chinese 
Association of Maternal and Child Health Studies (IRB201001). The participating couples 
were provided free preconception examination and healthcare services, and their personal 
information was kept anonymous.  
 
11 SUMMARY OF RESULTS 
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11.1 The Flow chart (Figure 9) demonstrates the number of participants included in 
each of the studies presented below. 
 
 
Figure 9. Number of participants included in each of the studies. 
 
11.2 China’s community-based strategy of universal preconception care in rural areas at 
a population level using a novel risk classification system for stratifying couples’ 
preconception health status 
During 2010-12, a total of 2142849 couples were included to the national preconception care 
project. 92.36% couples were from rural areas; 89.2% women and 88.3% men had education 
below university level. Among those couples aged 30–35 years and >35 years, Category D 
risk was more common, compared to those aged less than 30 years (P<0.05). More women of 
non-Han ethnicity had risk factors of category D and X compared to those of Han ethnicity. 
However, that ratio among men was not significantly different.  
68.29% (1463266) couples were with at least one preconception risk factor. The main factors 
were of category A, B and C. The rate of category A (avoidable) risk factor was 11.24%, with 
38.13% among men. 3.4% women drank and 0.45% smoked, but the rate was nearly 30% of 
men who reported to drink alcohol and smoke [40].  
11.3 Sero-epidemiological map of Toxoplasma gondii infection and associated risk 
factors in preconception period in China: a nation-wide cross-sectional study  
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2008561 married women had their Toxoplasma gondii serology test, and enrolled for this 
analysis. Generally, participating women was of young age (28.1±4.8 years), and 1545510 
(78.2%) women were occupied as a farmer. They were of lower education level: 89.6% 
(1634003) women had senior high school education or lower. Concerning of dietary habits, 
1.3% (25850) of women did not eat meat and egg, and 1.0% (19948) did not eat fresh fruits 
and vegetables. 0.3% (5212) women ate raw meat or fish, and 2.9% (57385) women reported 
their exposing to cats.  
2.3% (45405) women were Toxoplasma IgG positive and 0.3% (6884) for IgM positive. Only 
0.04% (859) women were with both IgG and IgM positive. Provincial (geographical) 
difference in IgG sero-positivity was significant: the highest was 11.2% in Tianjing and the 
lowest was 0.2% in Heilongjiang. Toxoplasma IgM sero-positivity ranged from 0.9% in 
Anhui, to 0% in Tibet.  
Regarding the risk factors of Toxoplasma gondii IgM positivity, maternal age, residence, 
occupation of farmer, vegetarian diet and exposure to cats were statistically significant 
(P<0.05). Moreover, those women ate raw meat or fish tended to be Toxoplasma IgG positive, 
whereas women with lower education level were more likely to be Toxoplasma IgM positive 
(P<0.05). After adjusting for province of residence, involvement in agricultural activitiesand 
exposure to cats, were statistically related with Toxoplasma gondii IgM sero-positivity 
(P<0.0001) [101]. 
11.4 Rubella virus immunization status 
A total of 1974188 women had Rubella IgG serology and reported vaccination history.  The 
average age of the participating women was 28 years and 76.7% (1613342) women were 
occupied as a farmer. 89.1% (1884504) women were of  high school education or lower. 
Overall, 58.4% (1161129) women were of Rubella virus IgG sero-positivity, and 4.6% 
(91604) women reported previous vaccination. IgG sero-positivity rates varied across the six 
administrative regions: the highest was in northeastern area (84.5%) while the lowest was in 
northwestern area (45.8%). The rates of Rubella IgG sero-positivity differed in 31 provinces: 
the highest rates were observed in Jilin (92.5%), Beijing (91.9%), Ningxia (82.3%) and 
Guangdong (81.0%), while the lowest rates were in Tibet (0.0%) and Qinghai (20.1%).  
The self-reported rate of Rubella virus vaccination status was lower among women aged 40-
49 years, compared with their countparts aged 20-29 and 30-39 years (P<0.0001). This rate 
appeared to be lower among women from urban areas compared to those from rural areas 
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(P<0.0001). In addition, there was no signifanct correlatation between Rubella IgG sero-
positivity and self-reported vaccination (P=0.07) [102]. 
11.5 Sero-epidemiology of Cytomegalovirus infection and its geographic and socio-
economic determinants in preconception period among Chinese women planning a 
pregnancy within six months: A nationwide study  
2019555 women who had their Cytomegalovirus serology tested were included in this CMV 
analysis. The overall Cytomegalovirus IgG sero-positivity rate was 42.1% (850592) and 0.4% 
(9290) were IgM positive indicating that nearly 60% women were at risk of Cytomegalovirus 
infection before conception (Table 1 in Paper IV). 
Provincial differences in Cytomegalovirus IgG sero-positivity ranged from 20.1% in Shaanxi 
to 97.5% in Zhejiang, besides the extreme low rate of 0% in Tibet and 0.2% in Heilongjiang, 
consistent with a substantial regional difference (Figure 1 in Paper IV). The highest IgM 
positive rate was observed in Liaoning of 2.3%, and the lowest rate was in Heilongjiang 
(0.1%) and Tibet (0%) (Table 2 in Paper IV). 
CMV sero-positivity was associated with province of residence after adjusting for age, 
education level and occupation by multivariate correlation analysis (P<0.0001).  
Analysis of correlation between CMV serology and socioeconomic factors demonstrated that 
provincial CMV IgG sero-positivity was statistically significantly correlated with resident 
consumption level (r=0.437; P=0.014), and but not with GDP (r =0.167; P=0.369). CMV IgM 
sero-positivity was neither significantly associated with GDP (r=0.229; P=0.216) nor with 
resident consumption level (r=0.049; P=0.794).  
 
12 DISCUSSION 
12.1 Main findings 
This thesis provides an overview of prevalence of preconception risk factors among married 
couples residing mostly in rural areas of China based on a novel integrated amenability-based 
risk classification model. Furthermore, it presents a sero-epidemiological map of TORC 
infections among women with pregnancy intention. Firstly, new stratification of risk 
classification model demonstrated that proportional prepregnancy risk factors could be 
eliminated or prevented by appropriate medical intervention. Secondly, an integrated 
approach to PCC including male partner is justified as more than half of the husbands 
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planning to father a child were exposed to risk factors prior to a pregnancy. Thirdly, it was 
demonstrated that TORC sero-positivity in preconception period in rural China had a 
substantial geographic variation and susceptibility to these vertically transmittable infections 
among women of childbearing age is substantially high.  
12.2 Methodological considerations 
Sero-epdemiology is a method that uses the measurement of antigens or antibodies in the 
serum to identify infectious stratus as well as immunity and susceptibility to infections in the 
population of interest. It is an excellent tool to study the prevalence of biomarkers of infection 
and/or vaccination [103]. We applied this approach to study population immunity in the 
preconception period and identified susceptibility to TORC infections among women with 
pregnancy intention in the following six months. Seroprevalence data provide reliable and 
useful information on population immunity and susceptibility to infections especially when 
the infections are subclinical. However, it is not always possible to differentiate between 
acquired immunity due to vaccination and natural immunity due to infection, meaningful 
estimates of vaccination coverage and effectiveness, as well as factors associated with disease 
resurgences can be stipulated based on such data. However, it is important that the sampling 
method used provides a representative sample of the population of interest for it to be useful 
and that the reliable laboratory assays are used. We believe that this government-sponsored 
project had sufficient nationwide coverage and quality control mechanisms in place, which is 
able to provide reliable data although the sampling was done from the rural, low resource 
areas of China. This project has provided much needed experience on implementing universal 
preconception care and integrating it into the national healthcare system. Despite the need for 
providing venous blood samples, it appears to feasible and acceptable to use 
seroepidemiological method for detecting susceptibility and immunity to TORC infections in 
a country as large as China. Further studies are required to evlaute whether such a strategy is 
feasible cost-effective in other countries. 
 
12.3 Limitation of the data 
The effect of risk classification on the couples’ health before conception did not be assessed 
because follow-up of pregnancy outcomes was not included in our study. It is unclear whether 
the counseling and advice provided lead to sustained risk modifications among couples. 
Secondly, there is a possibility of recall bias because dietary habits, exposure to cats, history 
of vaccination, adverse pregnancy outcomes and history of chronic disease, were mainly 
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based on self-reporting, although medical records and vaccination cards were scrutinized 
when available. Thirdly, there could be selection bias about low sero-positivity rate in Tibet 
because only 53 couples were included. Finally, different laboratories used different assay 
kits according to the local choice and might have used different cut-off values to indicate 
seropositivity although all of them were approved by the China Food and Drug 
Administration and central inspections and quality control mechanisms were in place. 
Therefore, we had to use sero-positivity and negativity as categorical variables rather than 
using antibody levels as the quantitative variables. Standardizing and uniformly using same 
assay kits could help to make comparisons between different locations and regions more 
reliable in the future. 
12.4 Novel amenability-based risk classification system adapted by NPHCP 
This nation-wide free project was an integrated model of PCC. It targeted rural areas in China 
and included both women and men. Based on the amenability of preconception risk factors, 
our novel classification system stratified enrolled couples into different risk categories.  
PCC is not routinely offered in most countries around the world, and where it is offered the 
focus has been mostly on women. Preconception risk evaluation for couples planning to 
conceive was expected to be meaningful: more than 60% of the recruited couples had risk 
factors, and moreover, 23% of maternal and 45% paternal risk factors were potentially 
avoidable or preventable. More importantly, the most common risk factors among male 
partners were smoking and alcohol consumption, which were avoidable before pregnancy.  It 
can be speculated that the alcohol and substance abuse may be associated with social 
problems and domestic violence, and partner smoking usually leads to passive smoking, 
which is related with adverse pregnancy outcomes. This underscores the importance of an 
integrated approach to PCC that includes not only women but their male parterners as well. 
Furthermore, the effectiveness of the interventions, such as health education, 
recommendations about life style changes, nutrition and medical prescriptions need to be 
further evaluated. In addition, in order to achieve sustained amelioration, some avoidable 
risks including smoking, alcohol consumption and substance abuse, calls for a longer-term 
strategy. 
In some European countries, there are PCC recommendations for women with diabetes or 
epilepsy, however, they are heterogeneous and inconsistent [104]. Therefore, PCC approach 
needs to be further innovated to achieve an optimal reproductive health status before 
conception and during pregnancy period [105-106]. Couples participating in this project who 
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were identified to have a significant medical condition or disease were referred to specialists. 
However, we are unaware of the exact content of the care they received after referral, and it 
may have varied in different healthcare institutions. In addition to PCC, more uniform 
evidence-based maternal health care would be required for managing risk categories C and D 
during pregnancy period to achieve better pregnancy outcomes.  
The classification system of preconception risk in this national PCC project was practical: it is 
helpful for stratifying the couples’ health status, targeting health interventions, and further 
referring to specialists. The risks were classified during the preconception period, but their 
amenability to modification was considered during both the preconception and the prenatal 
periods. Because new risks factors may emerge during pregnancy, prenatal risks may be 
different from preconception risks. Therefore, it is important to take into account of different 
methods and timing of intervention. PCC provides a window of opportunity for individual 
health promotion for motivated couples. Regardless of abundant supportive evidence for the 
value of PCC [107], there lacks sufficient research focused on clinical PCC service delivery. 
Thus, the implementation of PCC within contemporary women’s healthcare requires more 
consideration in details [108]. This national integrated free PCC service in rural China 
provides a promising model, and its effect on pregnancy outcomes needs fruther demonstrated 
in future. 
12.5 Sero-epidemiological map of Toxoplasma gondii infection and associated risk 
factors 
In this nation-wide study, we found the low rate of Toxoplasma gondii sero-positivity among 
Chinese women planning a pregnancy: 2.3% women were IgG positive, 0.3% were IgM 
positive, and 0.04% were both IgG and IgM positive. Among pregnant women in Jiangsu, 
Qingdao and Weihai, Toxoplasma gondii IgG sero-positivity varied from 3.8% to 15.2 %, and 
IgM from 1.6% to 2.9% [101, 109-110]. Our study reported a national sero-positivity rate for 
Toxoplasma gondii among women before pregnancy.  
Secondly, we found the geographical variation in Toxoplasma gondii sero-positivity: 
provincial rates differed: 0.2-11.2% for IgG and 0.0-0.9% for IgM. Vertical transmission was 
reported to be approximately 20% if maternal infection occurred during pregnancy, and 
moreover, the incidence was increased from the early to the late pregnancy [102]. Thus, to 
achieve prevention of congenital toxoplasmosis, more targeted strategies for primary 
prevention for women planning pregnancy should be emphazed.  
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Thirdly, occupation of farmer and exposure to cats were demonstrated as risk factors for 
Toxoplasma gondii infection. This was reasonable as it was more likely for a farmer to be 
exposed to cats and contaminated soil. Li et al. reported that the main infection source of 
Toxoplasma gondii among the Han population would be feeding a cat [66]. Despite that fact 
that exposure to cats and eating raw meat were known as risk factors for Toxoplasma gondii 
infection [68-68], further strategy is required for strengthening current insufficient personal 
hygiene [111]. Moreover, it was indicated that early antibiotic therapy was benefifical for 
eliminating severely affected infants, but prenatal treatment during pregnancy did not reduce 
the risk of maternal-fetal transmission [112]. Therefore, identifying infected women before 
conception provides an oppounity for primary prevention before pregnancy. Our findings 
were useful to integrate preconception care for reducing congenital toxoplasmosis in Chinese 
communities. 
12.6 Sero-epidemiological map of Rubella virus and immunization status 
We found that more than 40% women planning a pregnancy were susceptible to Rubella in 
Mainland China characterized with a significant regional difference. To our knowledge, there 
are no other similar nationwide studies to compare our results. In a previous study of female 
migrant factory workers in Shenzhen, 77.6% women were immune to Rubella [113]. The 
relatively low rate of Rubella IgG sero-positivity could possibly due to limitation of 
healthcare facilities and childhood vaccination in rural China. Targeted screening and 
vaccination for women before conception are indicated to reduce CRS in China. Moreover, to 
prevent CRS in future pregnancies, postpartum Rubella vaccination is also available for those 
sero-negative women in Japan and Spain [114-115]. Our study opened a window for better 
ensuring Rubella vaccination coverage among Chinese women in rural China. 
12.7 Sero-epidemiology of Cytomegalovirus infection  
We found that nearly 58% women were at risk of CMV infection before conception. Nation-
wide prevalence of CMV sero-positivity was very different from what has been reported in 
some pregnant populations previously. As an example, in our study the rate of IgG sero-
positivity in Jiangsu province was 47.6%, which is substantially lower than that reported 
among pregnant women (98.7%) from the same province [36]. Preconception serological 
screening might be useful in this situation as preventive strategies to minimize exposure to 




As congenital CMV infectionis mainly caused by vertical transmission, vaccines administered 
to adult women could reduce the burden of CMV in children by making them immune prior 
to pregnancy [116-117], but no approved vaccines are available yet. However, there is a 
growing evidence that CMV vaccination can protect adults and children from infection, and 
licensure paths have been defined [116-118]. Offering vaccination to susceptible women 
before conception could be possible in the near future.  
There was significant geographic variation in CMV sero-positivity among married women 
planning a pregnancy. This may be related to cultural and socio-economic differences. To our 
knowledge, socio-economic determinants of CMV infection in China have not been reported 
previously. We found that CMV serology status is associated with socio-economic factors. 
We found a significant correlation between provincial CMV IgG sero-positivity and resident 
consumption level, and GDP correlated with both CMV IgG and IgM sero-positivity. Thus, 
economic determinant should be considered when developing and implementing preventive 
strategies. 
12.8 Validity of the findings  
The internal validity of our data was ensured by the systematic identification and inclusion of 
almost all eligible women in rural China. Our trained local community staff used a uniform 
questionnaire survey in order to collect standardized family health file, and also utilized web-
based data entry to a centralized database. The government organized and conducted periodic 
quality controls. Some of the information collected in the project was based on self-reports, 
which may be prone to reporting and recall bias. Although uptake of folate, alcohol, and 
smoking were verified by biomarker testing, epidemiological mapping of population 
immunity and susceptibility to TORC infections in preconception period was based on 
serological screening.  
Possibility of experimental bias could not be avoided as the different reagents and kits were 
used based on local availability. Possibility of some cases being false positive or false 
negative could not be excluded, as the results of repeated testing were not included in the 
database. 
Regarding external validity, participating couples were all married and were of relatively 
young age, less educated, most were residing in rural areas and had a fairly homogeneous 
ethnic and socioeconomic background. In other words, they were representative of rural 
young couples in preparing for a pregnancy. Therefore, our findings are likely be valid and 
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applicable to several other low-middle income countries around the world, but may not be 
generalizable and directly applicable to urban populations living in economically affluent 
high-income countries. Furthermore, in this national project, PCC was free, but offered only 
to couples who were married and had clear plans regarding pregnancy. In China, having 
babies without being married is rare and most pregnancies are planned. This may not be the 
situation in many industrialized countries. Therefore, this model of PCC may not be directly 
transferrable to other countries and societies with different cultural backgrounds, social 
structures, and healthcare delivery systems.  
 
13 CONCLUSIONS 
Preconception health screening and use of risk novel risk classification system could 
effectively identify important risk factors and stratify couples into different risk categories. It 
is of importance to include male partners in preconception care, as more than half of the male 
partners were exposed to risk factors during the preconception period. A majority of the risks 
in our novel amenability-based risk classification model chould be avoidedor prevented, 
which suggested that integrating PCC in healthcare could be beneficial for improving 
pregnancy outcomes.  
Sero-epidemiological map of TORC infection showed that a significant proportion of women 
in rural China are susceptible before conception. Therefore, screening for these infections 
followed by appropriate referral, diagnosis, treatment, counseling, health education and 
vaccination before pregnancy should be taken into account to reduce the risk of vertical 
transmission during pregnancy and childbirth. Targeted preventative strategies are needed to 
tackle significant regional variations in susceptibility to TORC infections among women 
during preconception period. 
 
14 FUTURE PERSPECTIVES 
This project provided some important insights into a model of universal free PCC for couples 
with clear conception plans. Risk identification and stratification was feasible and use of 
serological screening was acceptable to couples and effective in establishing a sero-
epidemilogical map of TORC infections in preconception period. However, the effectiveness 
of subsequent interventions on pregnancy outcomes should be further evaluated. There are 
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several challenges, barriers, opportunities, and threats to offering universal free PCC to all 
couples planning a pregnancy.  
14.1 Challenges related to translation of research findings into healthcare practice  
Although there is sufficient evidence and consensus that at least some components of PCC are 
useful, it has not been universally implemented in healthcare practice. Since this project is 
mainly conducted in rural areas, the preconception risk profile among couples living in urban 
China is still lacking, and the PCC model of rural China needs to be expanded to urban areas. 
However, providing free PCC within the framework of national healthcare systems will 
require substantial resource allocation, and cost-effectiveness should be evaluated. The 
prepregnancy risks factors evaluated in NFHCP were chosen by experts based on the review 
of literatures. Importance of these risk factors and whether targeted PCC interventions work 
well needs further evaluation by comprehensive follow-up at the community level. 
Addressing wider social determinants of health, the impact of education, income, work and 
relationships on preconception health also needs to be addressed.  
14.2 Opportunities for health promotion during the whole span of reproductive life  
The current idea of PCC is to embed it into care pathways throughout a woman’s reproductive 
life. PCC is justified not just before conception, but across the whole span of reproductive 
years. Planning a pregnancy provides good motivation to improve health and an opportunity 
to maintain good reproductive as well as general health. The impact of PCC on general health 
across reproductive years needs to be explored in longitudinal studies. 
PCC is helpful for raising health awareness. The high coverage of this nationwide free PCC 
project has a potential for enhancing awareness about PCC and promoting health behavior 
among couples as well as their families. 
14.3 Threats to feasibility and effectiveness of PCC 
To provide an efficient PCC service, caregivers need to be appropriately trained. Before and 
during this PCC project, community staff and local doctors were specially trained. Also, 
training guidelines, standards and tools are developed to support them in delivering PCC 
efficiently. It is important to train new staff and maintain their knowledge and professional 




In China, a high uptake of PCC has been achieved using the current community based 
national healthcare system to deliver free PCC. Continued efforts will be required to maintain 
and improve the infrastructure at community level for the success of PCC delivery using this 
strategy. 
PCC is expected to provide health benefits resulting in healthier mothers and their offspring. 
However, its cost-effectiveness should be considered and evaluated before a universal PCC 
can be recommended. It is also important to evaluate each component of PCC to figure out 
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SUPPLEMENTARY MATERIALS  
 
English-translated Consent Form and Record Sample of the National 





Informed Consent for the National Preconception Health Examination Project 
The Chinese government provides a free preconception health examination for all the married 
couples in rural areas, aiming for a healthier baby and happier family. 
The National Preconception Health Examination Project (NPHCP) is provided 4-6 months 
before a planning pregnancy. The contents include health education, medical history 
collecting, physical examination, clinical laboratory tests, imaging test, risk evaluation and 
medical advice. The purpose is to find the risk factors leading to potential adverse outcomes 
as early as possible, to help the couples to know their health status and obtain a 
comprehensive health advise. It is beneficial for the married couples to achieve pregnancy in 
an ideal psychological and physiological status to prevent of birth defects and have a healthy 
baby. 
NPHCP focuses on identifying the most common and most important risk factors before 
conception that reflect the couple’s current health status. There still exists a possibility of 
birth defects or other adverse pregnancy outcomes (e.g. miscarriage, stillbirth, etc.), whether 
the preconception examination is normal or not. You are required to have a regular antenatal 
care during pregnancy. 
If you’re willing to participate in this project, please sign your name on this informed consent. 
Your personal information is will be kept strictly anonymous. 
___________________________________________________________________________ 
I have read the information described above and understood completely. I am willing to 
participate in the National Preconception Health Examination Project (NPHCP) and accept 
the follow-ups. 
Signatures: 
Husband:                             Date: 
Wife:                                       Date: 
Doctor:                                  Date:
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  No. ! ! ! ! ! ! ! ! ! ! ! ! ! 
 
Records of the National Preconception Health Examination Project 
County authority：       Province        County                             
Village/town authority：       Province        County        Village (town)             
Form 1. Basic information 
Husband’s Name          Race       Birth of Date      Age       Education level          
ID  ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! 
Job !  1.Farmer 2. Worker 3. Service provider 4. Business 5. Househusband 6. 
Teacher/officer/clerk 7. Others        
Residence      Province    City     County     Town      Village 
! 1.Rural 2. Urban  
Wife’s Name          Race       Birth of Date      Age       Education level          
ID  ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! 
Job !  1. Farmer 2. Worker 3. Service provider 4. Business 5. Housewife  
6. Teacher/officer/clerk 7. Others        
Residence      Province    City     County     Town      Village 
! 1.Rural 2. Urban  
Zip               Marriage time              Telephone                            
Doctor’s signature：                                          Date：                                              
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Form 2. Wife’s preconception Examination 
General information 
Disease history: 
□None □Anemia □Hypertension □Heart disease □Diabetes 
mellitus 








□Gonorrhea/trichomoniasis □Psychological or mental 
diseases 
Is there any birth defect, eg: congenital abnormality, genetic disease:  
□No □Yes                                                              
Is there any gynecological disease:  
History of drug use: 
Do you take any drug now? 
□No □Yes                                                              
Have you taken any immunization? 
□No □Rubella □HBV □Others                                    
Do you use any contraception? 







□Others                                        
□No □Infectious 
disease 
□Infertility  □Others                                
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Length of contraception      ：       
months 
Termination date:                
Pregnancy history: 
Age of first menstruation     years old        LMP date:                    
Is menstruation regular?       □No    □Yes（period   days  length       days 
Amount of menstruation   □Many  □Medium   □Little      
Dysmenorrhea    □No  □Light   □Heavy 
Did you ever be pregnant? 
□No □Yes: Pregnancy     times,  live birth    times (full term       times，preterm 
birth       times) 
Did you have any adverse pregnancy outcome previously? 
□No □Stillbirth/death 




Did you ever deliver a baby with birth defect, eg: abnormalities, genetic disease, Down’s syndrome 
□No □Yes                                                                          
Current child/children           Health status:  □healthy  □any disease                          
Family history: 
Do you have intermarriage with your husband? 
□No □Yes                                            
Did your grandparents or parents have intermarriage? 
□No □Yes                                            
Do your relatives have any following disease?  
□No □Mediterranean □Albinis □Hemophilia □G6PD 
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□Hearing impairment before 10 
years old 
□Visual impairment before 10 years old 
□Neonatal or infant death □Other birth defects                                     
Relationship with me                                                                 
Nutrition, behavior and environmental factors: 
Intake of meat and egg    □No    □Yes 
No intake of fresh vegetables       □No    □Yes 
Raw meat eating habit   □No    □Yes 
Smoking          □No    □Yes（      cigarettes/day） 
Second-hand smoking    □No    □Sometimes  □Often（       minutes/day） 
Alcohol drinking          □No    □Sometimes  □Often（       ml/day） 
Drug use    □No    □Yes                               
Halitosis          □No    □Yes 
Gingival bleeding     □No    □Yes 
Is there any exposure to the following risks? 
□No □Radiation □High 
temperature 
□Noise □Organic solvent 
□Close contact with pets □Shaking □Heavy mental □Pesticide 
□Others                                                                        
Social and psychological factors: 
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Do you feel any pressure in work    □No    □Seldom   □Sometimes   □Often   □Always 
Do you have a tense relationship with friends or colleagues? □No    □Less   □To some extent   
□Often   □always 
Do you have any economic pressure       □No    □Less   □To some extent   □Often   □Always 
Do you feel ready for a pregnancy             □No    □Yes 
Others                                                                     
Date：                                  Doctor’s signature：                        
 
Physical Examination 
Height      cm   
Weight       Kg   
Body mass index        kg/m2 
Heart rate      beats/minute   
Blood pressure    /     mmHg 
! Psychological status  0. Normal  1. Abnormal                    
! Intelligence     0. Normal  1. Abnormal (□common sense □judgment □memory 
□calculation) 
! Otorhinolaryngology  0. Normal  1. Abnormal                 
! Special facial features  0. Normal  1. Abnormal                   
! Skin and hair  0. Normal  1. Abnormal                 
! Thyroid  0. Normal  1. Abnormal                 
! Lung  0. Normal  1. Abnormal                 
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! Heart rhythm  0. Normal  1. Abnormal                 
! Auscultation of heart  0. Normal  1. Abnormal                 
! Liver and spleen  0. Normal  1. Abnormal                 
! Spine and limbs  0. Normal  1. Abnormal                 
Others                                                                     
Date：                                  Doctor’s signature：                        
 
Reproductive features：  
! Pubic hair  0. Normal  1. Abnormal                 
! Breast  0. Normal  1. Abnormal                 
Gynecological examination：  
! Vulva  0. Normal  1. Abnormal                 
! Vagina  0. Normal  1. Abnormal                 
! Vaginal discharge 0. Normal  1. Abnormal                 
! Cervix  0. Normal  1. Abnormal                 
Uterus   
□Size  0. Normal 1. Enlarged 2. Smaller   
□Mass 0. No  1. Yes                    
□Ovary of fallopian tube  0. Normal  1. Abnormal                                      
Date：                                  Doctor’s signature：                        




□Clue cell: 0.negative 1.positive 9.suspecious       
□Candida infection: 0.negative 1.positive 9.suspecious 
□Trichomoniasis: 0.negative 1.positive 9.suspecious  
□Cleanness: 0.Ⅰ  1.Ⅱ  2.Ⅲ  3.Ⅳ  
□Amine odor test:  0.negative 1.positive       
□PH value: 0. <4.5     1. ≥4.5 
□Gonorrhea screening: 0.negative 1.positive 9.suspecious 
□Chlamydia trachomatis screening: 0.negative 1.positive 9.suspecious 
Blood routine: 
Hb          g/L         
RBC       ×1012/L 
PLT        ×109/L 
WBC    ×109/L 
Neutrophils    %  
Eosinophils    % 
Basophils    %  
Lymphocytes   %  
Monocysites     % 
!  Urine routine:  




□ABO  1. Type A 2. Type B 3. Type AB 4. Type O 
□Rh  0. Positive  1. Negative 
Fasting blood sugar level        mmol/L 
Hepatitis virus B  0. negative 1. positive 9. suspicious 
!HBs-Ag   !HBs-Ab   !HBe-Ag    !HBe-Ab    !HBc-Ab 
Liver and renal function tests: 
Alanine aminotransferase（ALT）           U/L    
Creatitine（Cr）                 umol/L 
Thyroid function test: 
Thyroid stimulating hormone（TSH）                                          ulU/ml 
! Rubella virus   IgG: 0. negative 1. positive 9. suspicious      
! Rapid plasma regain  0. negative 1. positive 9. suspicious  
Cytomegalovirus ! IgG: 0. negative 1. positive 9. suspicious      !IgM 0. negative 1. 
positive 9. suspicious  
Toxoplasma ! IgG: 0. negative 1. positive 9. suspicious      !IgM 0. negative 1. positive 9. 
suspicious 
Others:                                                         
Date：                                  Doctor’s signature：                        
 
Gynecological imaging examination 
! Gynecological ultrasound  
0. Normal  1. Abnormal                 





























Form 3. Husband’s preconception Examination                                  
General information 
Disease history: 
□None □Anemia □Hypertension □Heart disease □Diabetes 
mellitus 








□Gonorrhea/trichomoniasis □Psychological or mental 
diseases 
Is there any birth defect, eg: congenital abnormality, genetic disease:  
□No □Yes                                                              
Is there any disease of reproductive system:  
History of drug use: 
Do you take any drug now? 
□No □Yes                                                              
Have you taken any immunization? 
□No □Rubella □HBV □Others                                    
Do you use any contraception? 







□Others                                        
□No □Infectious   
disease 
□Infertility  □Others                                
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Length of contraception      ：       
months 
Termination date:                
Family disease: 
Did your grandparents or parents have intermarriage? 
□No □Yes                                            

















□Hearing impairment before 10 
years old 
□Visual impairment before 10 years old 
□Neonatal or infant death □Other birth defects                                     
Relationship with me                                                                 
Nutrition, behavior and environmental factors: 
Intake of meat and egg    □No    □Yes 
No intake of fresh vegetables       □No    □Yes 
Raw meat eating habit   □No    □Yes 
Smoking          □No    □Yes（      cigarettes/day） 
Second-hand smoking    □No    □Sometimes  □Often（       minutes/day） 
Alcohol drinking          □No    □Sometimes  □Often（       ml/day） 
Drug use    □No    □Yes                               
Halitosis          □No    □Yes 
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Gingival bleeding     □No    □Yes 
Is there any exposure to the following risks? 
□No □Radiation □High 
temperature 
□Noise □Organic solvent 
□Close contact with pets □Shaking □Heavy mental □Pesticide 
□Others                                                                        
Social and psychological factors: 
Do you feel any pressure in work    □No    □Seldom   □Sometimes   □Often   □Always 
Do you have a tense relationship with friends or colleagues? □No    □Less   □To some extent   
□Often   □always 
Do you have any economic pressure       □No    □Less   □To some extent   □Often   □Always 
Do you get ready for a pregnancy             □No    □Yes 
Others                                                                     
Date：                                  Doctor’s signature：                        
Physical Examination 
Height      cm   
Weight       Kg   
Body mass index        kg/m2 
Heart rate      beats/minute   
Blood pressure    /     mmHg 
! Psychological status  0. Normal  1. Abnormal                    




! Otorhinolaryngology  0. Normal  1. Abnormal                 
! Special facial feature  0. Normal  1. Abnormal                   
! Skin and hair  0. Normal  1. Abnormal                 
! Thyroid  0. Normal  1. Abnormal                 
! Lung  0. Normal  1. Abnormal                 
! Heart rhythm  0. Normal  1. Abnormal                 
! Auscultation of heart  0. Normal  1. Abnormal                 
! Liver and spleen  0. Normal  1. Abnormal                 
! Spine and limbs  0. Normal  1. Abnormal                 
Others                                                                     
Date：                                  Doctor’s signature：                        
 
Reproductive features：  
! Pubic hair  0. Normal  1. Abnormal                 
! Laryngeal prominence  0. Normal  1. Abnormal                 
Andrology examination：  
! Penis  0. Normal  1. Abnormal                 
! Foreskin 0. Normal  1. Abnormal                 
! Testicle 0. Palpable, volume (ml) left    right      1. Unpalpable on left side 2. Unpalpable 
on right side 
! Epididymis  0. Normal  1. Abnormal                 
! Vas deferens  0. Normal  1. Abnormal                   
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! Vericocele  0. No  1. Yes, site       degree            
Date：                                  Doctor’s signature：                        
 
Lab testing 
!  Urine routine:  
0. Normal  1. Abnormal                                                  
Blood type: 
□ABO  1. Type A 2. Type B 3. Type AB 4. Type O 
□Rh  0. Positive  1. Negative 
Hepatitis virus B  0. Negative 1. Positive 9. Suspicious 
!HBs-Ag   !HBs-Ab   !HBe-Ag    !HBe-Ab    !HBc-Ab 
Liver and renal function tests: 
Alanine aminotransferase（ALT）           U/L    
Creatitine（Cr）                 umol/L 
! Rapid plasma regain   0. Negative 1. Positive 9. Suspicious  
Others:                                                         
Date：                                  Doctor’s signature：                        
Other examinations 
(Based on local authority) 
 
 





  No. ! ! ! ! ! ! ! ! ! ! ! ! ! 
   
Preconception Health Assessment 
（1st copy for participants, 2nd copy for county-based health authority, 3rd copy for 
village/town-based health authority）  
Name of wife                 Age                  Telephone              
Name of husband             Age                  Telephone              
Address       Province      County       Town      Village 
!1. Both of the couples have accepted preconception health examination, and there is no pre-
existing risk factor. Regular health education and advice is recommended. 
Recommendations:                                                    
                                                                  
!2. Either of the couple has accepted preconception health examination, and there is no pre-
existing risk factor. Your wife/husband is recommended to accept the preconception 
health care. 
Recommendations:                                                    
                                                                  
!3.There are some pre-existing risk factors before conception. Further medical care is 
recommended. 
Recommendations:                                                    
Date：                                  Doctor’s signature：                        
Participants：Wife                      Date：                         Husband                   Date：                        
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  No. ! ! ! ! ! ! ! ! ! ! ! ! ! 
 
Follow-up records in early pregnancy 
 (for county-based health authority) 
Name of wife                 Age                  Telephone              
Home Address       Province      County       Town      Village 
Follow-up authority:        Province      County 
 
Date of last menstruation period (LMP)                              
!Is last menstruation period correct   0 No    1 Yes   
!Timing of folic acid supplement   0. No 1. at least 3 months before LMP  2. 1-2 months 
before LMP  3. After LMP 
!Method of folic acid supplement    0. No 1. Regularly 2. Irregularly  
Intake of meat and egg    □No    □Yes 
No intake of fresh vegetables       □No    □Yes 
!Has your husband stopped smoking?      0. No  1. Stopped 2. Decreased  3. Unchanged 4. 
Increased 
!Have you stopped smoking?      0. No  1. Stopped 2. Decreased   3. Unchanged 4. Increased 
!Have you stopped drinking?      0. No  1. Stopped 2. Decreased   3. Unchanged 4. Increased 
!Have there existed the following risk factors?   0. No   1. Yes  
□exposure to cat or dog  
□pesticide  
□radiation  
□second-hand smoking  
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□others                             
! Have there existed the following symptoms?   0. No   1. Yes  
□vaginal bleeding     
□fever equal to 38.5℃ or above  
□diarrhea     
□abdominal pain 
□influenza  
□viral hepatitis   
□others                                                    
!Have you taken any drug after conception?  0. No  1. Yes                                  
!The medical authority you have confirmed pregnancy with 
1. This medical authority 
2. Referral to other medical authority 
□County-based medical service authority  
□County-base family planning service authority  
□Village or town based medical service authority            
□Village or town based family planning service authority 
□Other authority                                      ） 
!Urinary pregnancy test 0. I have not taken this test 1. Positive 2. Negative 3. Inconclusive  
!Ultrasound   0. I have not taken this test 1. Pregnant 2. Non-pregnant 3. Other findings                                                                  
!Your comments on preconception health examination  0. Very satisfactory  1. Satisfactory 
2. Medium  3. Bad  4. Very bad  
Date：                                  Doctor’s signature：                        
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  No. ! ! ! ! ! ! ! ! ! ! ! ! ! 
 
Follow-up records of pregnancy outcomes 
 (for county-based health authority) 
Name of wife                 Age                  Telephone              
Home Address       Province      County       Town      Village 
Follow-up authority:        Province      County 
! ! ! Pregnancy outcome:  
1. Normal live birth   
2 Preterm birth 
3. Low birth weight  
4. Birth defects (please complete the form of birth defects records) 
5. Spontaneous abortion 
6. Medical abortion  
7. Surgically induced abortion  
8. Ectopic pregnancy 
9. Stillbirth or neonatal death 
10. Other                                                                   
 If you have chosen 1, 2, 3, 4, 7, 9 for the question above, please continue to complete the 
following items: 
!Sex of baby   1. Male  2. Female  3. Hermaphroditism  4. Unknown     
 Birthweight        g 
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! Was it a multiple pregnancy?  1.Yes   2. No 
Date of delivery          
Gestational week at delivery          
Delivery site         Province            County 
! Site of delivery   1. Medical authority   2. At home  3. Other                                   
! Delivery method  1. Vaginal delivery   2. Vaginal assisted delivery  3. Cesarean section  4. 
Other                                       
! Health status of the baby within 42 day postpartum  
0. Not live birth   1. Alive  2. Neonatal death within 7 days after delivery  3. Neonatal death 
8-28 days after delivery  4. Neonatal death 28 days after delivery 
 




  No. ! ! ! ! ! ! ! ! ! ! ! ! ! 
 
Follow-up records of birth defects 
 (for county-based health authority) 
 
1. Family information 
Father Name           Age       (years) Race           ID No.                      
Mother Name          Age       (years) Race           ID No.                      
Pregnancy                Parity               
□ Residence  1.Urban    2.Rural 
Home address                                        
Zip              
Telephone                
2．Baby’s information 
Date of birth           
Sex of baby   1. male  2. female  3. hermaphroditism  4. unknown 
Delivery week        
Birthweight       g              
□Number of baby  
1. Singleton  2. Twin pregnancy 3. Multiple pregnancy with triplets or higher order 
□Outcome   
1. Alive  2. Neonatal death within 7 days after delivery  3. Neonatal death 8-28 days 
after delivery  4. Neonatal death 28 days after delivery 
Diagnosis criteria   
□clinical   □ultrasound   □autopsy   □alpha fetoprotein   □chromosome  □others 
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□timing of diagnosis   




02 Spina bifida……………………! 
03 Encephalocele…………………! 
04 Congenital hydrocephalus……! 
05 Cleft palate……………………! 
06 Cleft lip………………………! 
07 Cleft lip and cleft palate……! 
08 Microtia………………………! 
09 Other abnormality of ear………! 
10 Atresia or stricture of esophagus! 
11 Atresia or stricture of anorectal! 
12 Hypospadias……………………! 
13 Ectropion of bladder…………! 
14 Left clubfoot…………………! 
   Right clubfoot………………!  
15 Left polydactylism……………! 
  Right polydactylism ……………! 
16 Left syndactylia ……………! 
  Right syndactylia ……………! 
17 Limb shortening 
  Left upper limb…………… ! 
  Right upper limb …………… ! 
  Left lower limb………………!  
  Right lower limb ……………! 
 18 Congenital diaphragmatic hernia 
! 
19 Exomphalus……………… ! 
20 Gastroschisis……………… ! 
21 Conjoined twins…………… ! 
22 Down’s syndrome…………! 
23 Congenital heart disease…… ! 
24 Others………………………! 
                                         
                                               
                                            













□Hepatitis（type           ） 
□Others 
Drug use 
□Sulfanilamide               
□Antiboitics                 
□Contraception                
□Sedative                   
□Others                     
 
Exposure to harmful 
substance 
□Pesticide             
□Radiation             
□Alcohol             
□Chemical substance            
□Others             
5．□Diagnosis in   
（1）Provincial hospitals    （2）City-based     （3）County based    （4）others                  
    Date：                 Authority:                 Doctor’s signature：                        
 
